Harvard Bioscience Consolidates Manufacturing Operations

Streamlining production to improve efficiency and support long-term growth

Jan. 29, 2026 at 9:39pm

Got story updates? Submit your updates here. ›

Harvard Bioscience, a leading developer and manufacturer of life science technologies, announced a strategic consolidation of its manufacturing operations. The company will close its facility in Holliston, MA and transition U.S. production to its hub in Minneapolis, MN, while also relocating certain operations to facilities in Germany, Sweden, and the UK. This initiative is expected to deliver approximately $3 million in cost savings in 2027 and $4 million in annual cost savings beginning in 2028, while improving throughput and execution.

Why it matters

The consolidation represents a meaningful step forward in simplifying Harvard Bioscience's manufacturing footprint and strengthening its operating model. By concentrating U.S. manufacturing and relocating certain operations to international facilities, the company aims to better leverage the scale, capabilities, and expertise of its sites, improving execution and increasing speed-to-market as it builds a more agile organization to drive long-term value creation.

The details

Harvard Bioscience will close its Holliston, MA manufacturing facility and transition U.S. production to its hub in Minneapolis, MN. Certain operations will also be relocated to facilities in Germany, Sweden, and the UK, aligning specific product lines with their designated center of excellence and most strategically advantageous logistical location. The Holliston facility will remain operational throughout 2026 to support continuity and customer service, with the consolidation expected to be completed by the first quarter of 2027.

  • The consolidation is expected to be completed by the first quarter of 2027.
  • The Holliston facility will remain operational throughout 2026 to support continuity and customer service.

The players

Harvard Bioscience, Inc.

A leading developer, manufacturer and seller of technologies, products and services that enable fundamental advances in life science applications, including research, drug and therapy discovery, bio-production and preclinical testing for pharmaceutical and therapy development.

John Duke

CEO of Harvard Bioscience.

Got photos? Submit your photos here. ›

What they’re saying

“Building upon the enhanced flexibility provided by our recent refinancing, this consolidation represents a meaningful step forward in simplifying our manufacturing footprint and strengthening our operating model.”

— John Duke, CEO

What’s next

The company has implemented a comprehensive, phased transition plan designed to prevent any disruption to order fulfillment, product quality, and technical support.

The takeaway

This consolidation is expected to improve Harvard Bioscience's manufacturing efficiency, strengthen its operating model, and accelerate cost-savings efforts, positioning the company for long-term growth and value creation.